Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 with chemotherapy with or without JS015 as first-line treatment for MSS/pMMR advanced colorectal cancer
CTR20250831Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JS207, JS015 in colorectal cancer (CRC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2025; status: active.
02
Drugs
JS207JS015
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20250831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250831.